Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. According to a SEC filing for the period ended September 30, Saturn V Capital ...
Dyne Therapeutics, Inc. has announced a $275 million non-dilutive senior secured term loan facility with Hercules Capital, which includes an upfront funding of $100 million and the potential for an ...
- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - In Japan, Orphan Drug designation ...
- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER ...
Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...
The person behind the upgrade was Jay Olson of Oppenheimer. Before market open, he changed his recommendation on Dyne stock to outperform (buy, in other words) from his previous perform (hold). He ...
Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical ...
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
Hosted on MSN
Dyne Therapeutics shares rise after announcing positive topline results for z-rostudirsen in phase 1/2 DMD trial
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now. On December 8, Dyne Therapeutics announced positive topline results from the Registrational Expansion ...
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for ...
Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. The overall position increased in value by $20 million from quarter to quarter. Saturn ...
An analyst upgraded his recommendation on the biotech. He now feels it's worthy of a buy, and what's more, he almost quadrupled his price target. 10 stocks we like better than Dyne Therapeutics › Dyne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results